Brooklyn FI LLC Increases Its Investment in Johnson & Johnson

Brooklyn FI LLC has made a significant increase in its investment in Johnson & Johnson (NYSE:JNJ). During the fourth quarter, the firm raised its stake by an astounding 6,239.7%, as revealed in its latest Form 13F filing with the Securities and Exchange Commission (SEC). After acquiring an additional 125,668 shares during this period, Brooklyn FI LLC now holds a total of 127,682 shares of Johnson & Johnson, valued at approximately $19,795,000.

Other Institutional Investors Modify Holdings

Brooklyn FI LLC is not alone in adjusting its position in Johnson & Johnson. Other institutional investors have also made changes to their holdings. For example, Enhancing Capital LLC entered a new investment in the company during the fourth quarter, worth $2,256,000. Similarly, Xponance Inc. upped its stake by 6.2%, owning 389,251 shares valued at $56,293,000 after acquiring an additional 22,578 shares. Boston Partners raised its stake by a notable 23.7%, holding 2,263,067 shares valued at $327,306,000 following an additional purchase of 433,607 shares over the quarter. Additionally, Intech Investment Management LLC increased its holdings by 14.1%, now owning 121,824 shares worth $17,618,000 after buying 15,098 extra shares. Lastly, Horizon Investments LLC boosted its stake by 10.1%, acquiring 2,361 additional shares to own a total of 25,627 shares valued at $3,706,000. Currently, institutional investors hold about 69.55% of the stock.

Insider Transactions

In recent news regarding insider activity, Executive Vice President Timothy Schmid sold 403 shares of Johnson & Johnson on February 18th at an average price of $156.15. This transaction totaled $62,928.45. After this sale, Schmid holds 15,098 shares worth approximately $2,357,552.70, representing a 2.60% decrease in ownership. Furthermore, on February 25th, Vice President Robert J. Decker sold 6,999 shares at an average price of $165.88, resulting in total proceeds of about $1,160,994.12. This brought Decker's total holdings to 21,001 shares, valued at $3,483,645.88, which marks a 25.00% reduction in their stock ownership. Currently, corporate insiders hold about 0.16% of the total stock.

Current Stock Performance

As of Wednesday, JNJ stock opened at $164.24. The stock's 50-day moving average stands at $155.73, with a 200-day moving average of $156.25. Over the past year, Johnson & Johnson's stock has seen a low of $140.68 and a high of $169.99. The company's market metrics include a debt-to-equity ratio of 0.43, a current ratio of 1.11, and a quick ratio of 0.86. Johnson & Johnson has a market cap of approximately $395.80 billion, with a price-to-earnings (P/E) ratio of 24.70 and a price-to-earnings growth (PEG) ratio of 2.56.

Earnings Report Overview

On January 22nd, Johnson & Johnson reported its quarterly earnings, announcing earnings per share (EPS) of $2.04 which surpassed analysts' expectations of $1.99. The company reported revenues of $22.52 billion, beating the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Compared to the same quarter from the previous year, the quarterly revenue increased by 5.3%, although the EPS for that last quarter was $2.29. Analysts forecast an EPS of $10.58 for the current fiscal year.

Dividend Updates

Recently, Johnson & Johnson announced a quarterly dividend, which was distributed on March 4th. Shareholders of record as of February 18th received a dividend of $1.24 per share, resulting in an annualized dividend of $4.96 and a yield of 3.02%. The dividend payout ratio stands at 74.59%.

Analyst Ratings and Forecasts

Johnson & Johnson has been the subject of multiple analyst reports lately. Morgan Stanley lowered its price target from $175.00 to $163.00, maintaining an 'equal weight' rating. Wells Fargo & Company adjusted their target from $166.00 to $152.00, also setting an 'equal weight' rating. Barclays increased its target from $159.00 to $166.00 while retaining an 'equal weight' rating. Guggenheim reaffirmed a 'neutral' rating on JNJ shares, and Argus upgraded their rating to 'strong-buy'. In total, nine analysts rate the stock as a hold, eight as buy, and two as strong buy. Based on MarketBeat.com data, Johnson & Johnson holds an average rating of 'Moderate Buy' and a consensus price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company engaged in the research, development, manufacturing, and marketing of products within the healthcare sector. The company operates primarily through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on diverse areas such as immunology, infectious diseases, neuroscience, oncology, cardiovascular health, metabolism, and pulmonary hypertension.

investment, stock, changes